Allergen Specific IgE

Accreditation Status: UKAS Schedule of Accreditation

Date Scheme started: 1988

Clinical Applicability: Diagnosis and management of allergic disease

Analytes: The programme includes the assessment of common or clinically important, individual IgE specificities, for example:

D1	Dermatophagoides pteronyssinus
E1	Cat epithelium
E5	Dog dander
F1	Egg white
F2	Cow's milk
F13	Peanut
F17	Hazel nut
G6	Timothy grass
I1	Bee venom
I3	Wasp venom
K82	Latex
M3	Aspergillus fumigatus
M6	Alternaria alternata
T3	Birch
W6	Mugwort

Other allergen specificities may be included, subject to the availability of clinically validated donor serum units

Units for Reporting: Grade and kU/L (arbitrary)

Samples Distributed: Liquid format. Normal and pathological human

Number of Distributions per year: 6

Number of Samples per Distribution: 2

Frequency of Distributions: Every two months as outlined in the **Distribution Schedule**. Four allergen specific IgE tests will be analysed on each specimen

Schedule of Analysis: **Data entry** is via the web for the submission of results. Data analysis is commenced 21 days after sample dispatch. Late returns are accepted and will contribute to the laboratory's cumulative performance statistics

Data Analysis: Analysis by grade shows the overall response and the method specific responses. Analysis of the quantitative responses in Units shows the All Laboratory Trimmed Mean (ALTM) with truncation at 2SD, SD and CV%. Reports show method specific statistics. Individual laboratory performance is expressed in terms of MRBIS, SDBIS and MRVIS, the DV for calculation of VI being taken from the MLTM

Chosen Coefficient of Variation for Allergen Specific IgE is 12%

Performance Scoring: Cumulative performance scores are based on the quantitative response with MRVIS scoring over a running window of twelve samples or twelve months

© Copyright 2021 UK NEQAS for Immunology, Immunochemistry & Allergy

Criteria of Performance:

Performance assessment is allergen specific. Quantitative performance is assessed for each allergen, and is over a running period of 6 distributions containing that allergen (12 months)

Ideal	MRVIS	<50
Good		50 - 100
Adequate		101 - 200
Poor		>200 or SDBIS >200

The overall quantitative performance is expressed as the OMRVIS, the mean of all the individual allergen specific MRVIS

The semiquantitative Grades are assessed by MI scoring in relation to the Consensus Designated Response (CONDR). (For this purpose, Grades 2 – 6 are considered as CLEAR POSITIVE)

Good	OMIS	Zero
Adequate		1 - 3
Poor		>4

Overall MIS (OMIS) greater than 4 will also be considered as poor performance

Persistent Poor Performance:

Defined as being in the Poor Performance category for two or more successive distributions

© Copyright 2021 UK NEQAS for Immunology, Immunochemistry & Allergy